Inhibition of growth and regulation of IGFs and VEGF in human prostate cancer cell lines by Shikonin analogue 93/637 (SA)

Anticancer Research

Volumn 20, Issue 4, 2000, Pages 2547-2552

  Gaddipati, Java P ^a   Mani, Haresh ^a,b   Shefali, ^c   Raj, Kanwal ^c   Mathad, Vijayvitthal T ^c   Bhaduri, Amiya P ^c   Maheshwari, Radha K ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b ARMED FORCES MEDICAL COLLEGE   (India)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

IGF; IGFBP; Metastatic; Prostate cancer; Shikonin analogue 93 637 (SA); VEGF

Indexed keywords

LACTATE DEHYDROGENASE; MESSENGER RNA; SHIKONIN DERIVATIVE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; VASCULOTROPIN;

ARTICLE; CANCER CELL CULTURE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL SURVIVAL; ENDOTHELIAL GROWTH FACTORS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; L-LACTATE DEHYDROGENASE; LYMPHOKINES; MALE; NAPHTHOQUINONES; PROSTATIC NEOPLASMS; RECEPTORS, SOMATOMEDIN; RNA, MESSENGER; SOMATOMEDINS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033866725     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Shukla YN; Tandon JS; Bhakuni DS and Dhar MM: Chemical constituents of the antibiotic fraction of Arnebia nobilis. Experientia 25: 357-358, 1969.
2. Papageorgiou VP, Assimopoulou AN, Couladouros EA, Hepworth D and Nicolaou KC: The chemistry and biology of Alkannin, Shikonin, and related Naphthazarin natural products. Agnewwandte Chemie. Int Ed 55: 271-300, 1999.
3. Ahn BZ, Baik KU, Kweon GR, Lim K and Hwang BD: Acylshikonin analogues: synthesis and inhibition of DNA topoisomerase-1. J Med Chem 35: 1044-1047, 1995.
4. Seto Y, Motoyoshi S, Nakamura H, Imuta J, Ishitoku T and Isayama S: Effect of shikonin and its derivatives, pentaacetylated shikonin (MDS-004) on granuloma formation and delayed-type allergy in experimental animals. Yakugaku (Japan) Zasshi 112: 259-271, 1992.
5. Katti SB, Shukla YN and Tandon JS: Arnebin derivatives for anticancer activity. Indian J Chem 18: 440-442, 1979.
6. Shukla YN, Tandon JS and Dhar M: Arnebin-7, a new naphtha-quinone from Arnebia nobilis. Indian J Chem 11: 528-529, 1973.
7. Gupta SK and Mathur IS: The effect of Arnebia nobilis and its naphthaquinones in rat Walker carcinoma. Indian J Cancer 9: 50-55, 1972.
8. Plyta ZF, Li T, Papageorgiou VP, Mellidis AS, Assimopoulou AN, Pitsinos EN and Couladouros EA: Inhibition of topoisomerase I by naphthoquinone derivatives. Bioorganic and Medicinal Chemistry letters 8: 3385-3390, 1998.
9. Fujii N, Yamashita Y, Arima Y, Nagashima M and Nakamo H: Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones, plumbagin and shikonin. Antimicrob Agents Chemother 36: 2589-2594, 1992.
10. Grimberg A, Rajah R, Zhao H and Cohen P: The prostatic IGF system: new levels of complexity. In: Takano K, Hizuka N and Takahashi SI: ed. Molecular mechanisms to regulate the activities of insulin-like growth factors. Amsterdam, Elsevier, 205-215, 1998.
11. Wang YZ and Wong YC: Sex hormone-induced prostatic carcinogenesis in the noble rat: The role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 35: 165-177, 1998.
12. Chan JM, Stanfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH and Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279: 563-566, 1998.
13. Wolk A, Mantzoros CS, Anderson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D; Insulin-like growth factor-I and prostate cancer risk: a population-based, case-control study. J National Cancer Inst 90: 911-915, 1998.
14. Li S-L, Goko H, Xu Z-D, Kimura G, Sun Y, Kawachi MH and Yoko F-Y: Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 291: 469-479, 1998.
15. Iwamura M, Sluss PM, Cassmento JB, Cockett ATK, Casamento JB and Cockett AT: Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22: 243-252, 1993.
16. Hampel OZ, Kattan MW, Yang G, Haidacher SJ, Saleh GY, Thompson TC, Wheeler TM and Marcelli M: Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol 159: 2220-2225, 1998.
17. Rajah R, Valentins B and Cohen P: Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-b1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272; 12181-12188, 1997.
18. Albiston AL and Herington AC: Cloning and characterization of the growth hormone-dependent insulin-like growth factor binding protein (IGFBP-3) in the rat. Biochem Biophys Res Commun 166: 892-897, 1990.